PMID- 22040539
OWN - NLM
STAT- MEDLINE
DCOM- 20120325
LR  - 20221207
IS  - 2542-5641 (Electronic)
IS  - 0366-6999 (Linking)
VI  - 124
IP  - 19
DP  - 2011 Oct
TI  - Clinical significance of chromosomal abnormalities detected by interphase 
      fluorescence in situ hybridization in newly diagnosed multiple myeloma patients.
PG  - 2981-5
AB  - BACKGROUND: Chromosome 13q14 deletion (del13q14), chromosome 1q21 gain (amp1q21) 
      and chromosome 17p13 deletion (del17p13) are the most frequent chromosomal 
      aberrations in multiple myeloma (MM). They play an important role in prognosis. 
      The aim of this study was to investigate the clinical significance of the 
      chromosomal changes in Chinese MM patients. METHODS: Interphase fluorescence in 
      situ hybridization (FISH) on bone marrow (BM) cells was performed in 72 enrolled 
      MM patients. Relationships between chromosomal abnormalities and clinical 
      features, response to therapies and prognosis were analyzed. RESULTS: As a result 
      of interphase FISH, 77.8% (56/72) patients had chromosome changes. The incidences 
      of each probe were RB1 51.4% (37/72), D13S319 47.2% (34/72), 1q21 45.8% (33/72) 
      and p53 22.2% (12/72). Osteolytic lesion, BM plasma cells index, serum calcium 
      and serum M component were significantly correlated to del13q14. BM plasma cells 
      and hemoglobin were correlated to amp1q21. Serum lactate dehydrogenase (LDH) was 
      correlated with del17p13. Patients with del13q14 treated with bortezomib had a 
      notably higher overall response rate than the patients treated with traditional 
      chemotherapies (93% vs. 65%, P = 0.048). Patients carrying amp1q21 or/and 
      del17p13 did not achieve satisfactory response to bortezomib. The median 
      progression-free survival (PFS) for patients with amp1q21 was 5 months and 
      patients without amp1q21 got 9-month PFS (P = 0.001). The median PFS for patients 
      with del13q14 was 5 months (vs. 8 months, P = 0.026). The median PFS for patients 
      with del17p13 was 3 months (vs. 8 months, P = 0.002). Patients with 
      beta(2)-microglobulin > 5.5 mg/L also had a worse outcome, whose median PFS was 5 
      months (vs. 8 months, P = 0.016). CONCLUSIONS: The prevalence of chromosomal 
      abnormalities of MM patients was similar in Chinese and Caucasian people. Genetic 
      changes were associated with patients' responses to therapies and prognosis.
FAU - Hu, Yu
AU  - Hu Y
AD  - Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology, Wuhan, Hubei 430022, China. dr_huyu@126.com
FAU - Chen, Lei
AU  - Chen L
FAU - Sun, Chun-Yan
AU  - Sun CY
FAU - She, Xiao-Mei
AU  - She XM
FAU - Ai, Li-Sha
AU  - Ai LS
FAU - Qin, You
AU  - Qin Y
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - China
TA  - Chin Med J (Engl)
JT  - Chinese medical journal
JID - 7513795
SB  - IM
MH  - Adult
MH  - Aged
MH  - Asian People
MH  - *Chromosome Aberrations
MH  - Chromosome Deletion
MH  - Humans
MH  - *In Situ Hybridization, Fluorescence
MH  - Interphase
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/drug therapy/*genetics
MH  - Prognosis
EDAT- 2011/11/02 06:00
MHDA- 2012/03/27 06:00
CRDT- 2011/11/02 06:00
PHST- 2011/11/02 06:00 [entrez]
PHST- 2011/11/02 06:00 [pubmed]
PHST- 2012/03/27 06:00 [medline]
PST - ppublish
SO  - Chin Med J (Engl). 2011 Oct;124(19):2981-5.